Straumann stock reports 7.8 percent organic sales growth

Straumann stock (ISIN CH1175448666) was trading at CHF 97.14 on SIX on September 24, 2026. The share price stood 11.53 percent below its 52-week high of CHF 109.80, while the dental technology group delivered 7.8 percent organic sales growth in the first half of 2026.

H1 sales grow 7.8 percent

According to Stock Sentinel on September 14, 2026, Straumann generated CHF 1,379.5 million in H1 2026 sales, up 7.8 percent organically from the prior-year period. The result matched the cited consensus of CHF 1.37 billion.

The earnings quality also improved. Core EBIT reached CHF 354.8 million, slightly above the CHF 350.0 million consensus cited in the same H1 2026 report, while the constant currency core EBIT margin increased 120 basis points to 26.9 percent.

Profitability drives analyst view

Core net profit rose 15.7 percent to CHF 262.0 million in H1 2026, and free cash flow increased 49 percent to CHF 168.6 million. The combination of sales growth and margin expansion gives the operating result greater weight than the share price alone.

Goldman Sachs upgraded Straumann to Buy from Neutral on September 14, 2026, and raised its price target from CHF 106 to CHF 125, according to Investing.com. The bank forecast 9.9 percent earnings growth for fiscal 2027 and said Asia Pacific trends could support second-half 2026 sales.

On September 24, 2026, MarketScreener reported that Bernstein maintained a Buy recommendation and raised its price target, citing expectations for consistent execution in the second half. That assessment aligns with the 120 basis point margin improvement reported for H1.

Stock remains below yearly high

Straumann shares were trading at CHF 97.14 on SIX on September 24, 2026, down 0.08 percent on the session. The 52-week range was CHF 73.02 to CHF 109.80, placing the stock 11.53 percent below its yearly high and 33.03 percent above its yearly low.

More news and analyses on Straumann stock